Fig. 2: Genetic and expression profiles of the SCLC cohort.
From: FOXA2 promotes metastatic competence in small cell lung cancer
a Sample selection schema of never-metastatic (left) and metastatic SCLC. Created in BioRender. Rudin C. (2025) https://BioRender.com/qkiri1o. b Prevalent mutations in never-metastasized primary SCLC and metastatic SCLC cohort. c Heatmap of never-met primary SCLC, metastasis-associated (met-associated) primary SCLC, and metastatic SCLC. d Heatmap of never-met primary SCLC and met-associated primary SCLC. e Heatmap of never-met primary SCLC and metastatic SCLC. f Overlapping factors from panel (d, e). The data are analyzed with Wald’s test and 8 transcription factors were nominated following the criteria of FC > 4 or FC < −4, Padj < 0.05. The number of transcription factors is indicated in brackets. g Violin plot of expression for each of the 8 candidates based on scRNA-seq data of primary SCLC. h Volcano plot of candidate genes in bulk RNA-seq data comparing the expression of met-associated primary SCLC to never-met primary SCLC. i UMAP of FOXA2 in each component from scRNA-seq. j FOXA2 expression in primary SCLC with or without lymph node (LN) metastasis from the data of Liu Q et al. Graph is shown as mean ± SEM (* < 0.05, P = 0.04, two-sided Student’s t-test).
